Testing version — LOERadar is in active testing. Features and data may change.

TROXYCA ER (NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE) | LOERadar

Viewing data from:

TROXYCA ER

NDA

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | N207621 | PFIZER INC

6 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2027

2028

Today

Dec. 12, 2027

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

4 letters from Drugs@FDA

Date	Submission	Document
May 31, 2017	SUPPL -5	View Letter (PDF)
Dec 21, 2016	SUPPL -4	View Letter (PDF)
Oct 3, 2016	SUPPL -1	View Letter (PDF)
Aug 19, 2016	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (6)

Sort:

#001 — 1.2MG;10MG

1 patent0 exclusivities▴

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7815934	Dec 12, 2027	—	—	Yes	—	—

#002 — 2.4MG;20MG

1 patent0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016

#003 — 3.6MG;30MG

1 patent0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016

#004 — 4.8MG;40MG

1 patent0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016

#005 — 7.2MG;60MG

1 patent0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016

#006 — 9.6MG;80MG

1 patent0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 19, 2016